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Summary
The genus Mycobacterium consists of over 120 known species, some of which
(e.g. M. bovis and M. tuberculosis) contribute extensively to the burden of infec-
tious disease in humans and animals, whilst others are commonly found in the
environment but may rarely if ever be disease-causing. This paper reviews the
mycobacteria found in southern Africa, focussing on those in the M. tuberculosis
complex as well as the non-tuberculous mycobacteria (NTM), identifying those
found in the area and including those causing disease in humans and animals,
and outlines some recent reports describing the distribution and prevalence of
the disease in Africa. Difficulties in diagnosis, host preference and reaction,
immunology and transmission are discussed.
Introduction
Tuberculosis (TB) commonly occurs in humans and animals
throughout the world, with Africa and particularly South
Africa being a very high burden region, with the incidence of
M. tuberculosis in humans averaging 913/100 000 per annum
(World Health Organization). Detailed and thorough preva-
lence surveys are rarely carried out, but the few that have
been performed show that infection with M. tuberculosis,
the causative agent for TB in humans, is far more common
than estimated from passive case finding (den Boon et al.,
2007). South Africa currently has the highest global burden
of human disease fromM. tuberculosis. It is not the purpose
of this manuscript to reiterate that situation, other than to
remark that the situation is complex, given that we know
that the genus Mycobacterium, to which M. tuberculosis
belongs, consists of a larger group of species, most of which
have been shown to be able to cause different forms of myco-
bacterial disease under appropriate conditions (Phillips and
von Reyn, 2001; Petrini, 2006; Warren et al., 2006; Moore
et al., 2010; Simons et al., 2011). The fast-growing species
(<7 days in culture) are often non-pathogenic, whereas
slow-growing species (more than 7 days in culture) are
mostly pathogenic (see Fig. 1). The slow-growing species
include the members of the M. tuberculosis complex. Other
species outside the complex are known as the non-tubercu-
lous mycobacteria (NTM). Prevalence surveys, where
mycobacterial speciation has been carried out, have shown
that NTM may be up to three times more commonly found
in humans than M. tuberculosis (Muyoyeta et al., 2010 and
our own unpublished data). Similarly, although M. bovis is
the most common cause of tuberculosis in animals, it cannot
always be assumed to be the causative agent of tuberculosis
in animals.
The genus Mycobacterium currently consists of around
128 validly published species and five subspecies with at
least a further 34 species not fully described or named (van
Helden et al., 2009). They are commonly encountered in
the environment, where niches include water, soil, protozo-
ans, domestic and wild animals, invertebrates, and milk
and food products (Holland, 2001; Michel et al., 2007; Fal-
kinham, 2010). Some are obligate or opportunistic patho-
gens, but many are saprophytes. Apart from the common
and well-known pathogenic mycobacteria that are primar-
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ily transmitted between hosts, the environment can be a
source of exposure to mycobacteria. We have investigated
water as a source for such and found M. terrae, M. vaccae
(or vanbaalenii), M. engbaekii and M. thermoresistibile
(Michel et al., 2007). Although not extensively investigated,
there is clearly regional variation in the occurrence of
mycobacterial species, for example, M. ulcerans has not
(yet) been found in southern Africa. However, with the
movement of animals (and birds) often uncontrolled, one
can expect the unexpected (e.g. the occurrence of M. orygis
in South Africa (Gey van Pittius et al., 2012a,b).
Mycobacterium tuberculosis complex members
Mycobacteria grouped in the Mycobacterium tuberculosis
complex (MTBC) are characterized by what is regarded
as more than 99% similarity at the nucleotide level and
identical 16S rRNA sequences. The traditional members of
the Mycobacterium tuberculosis complex include the follow-
ing four species:Mycobacterium tuberculosis,Mycobacterium
africanum,Mycobacterium microti andMycobacterium bovis.
Newly recognized additions to the MTBC include Myco-
bacterium caprae, Mycobacterium pinnipedii and Mycobacte-
rium canettii, as well as potentially rarer or perhaps more
geographically restricted MTBC variants, such as the
so-called dassie (Parsons et al., 2008a) and oryx bacillus,
now known as Mycobacterium orygis (Gey van Pittius et al.,
2012a,b; van Ingen et al., 2012b) andMycobacterium mungi,
which causes TB in the banded mongoose (Alexander et al.,
2010).
Infection of animals or humans by the members of the
MTBC, most particularly M. tuberculosis and M. bovis, is
Fig. 1. The genus Mycobacterium. Well-known pathogens are mostly slow growers. The species marked in bold and with a * are NTM isolated in
South Africa from animals. Figure adapted from (Gey van Pittius et al., 2006).
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clearly of concern, as these are the commonly recognized
causes of the massive global burden of TB. Standard molec-
ular tools used to delineate and speciate the MTBC are
IS6110 restriction fragment length polymorphism (RFLP)
analysis; spacer oligonucleotide typing (spoligotyping);
regions of difference (RD) analysis and MIRU-VNTR typ-
ing. These tools can be used to position the different mem-
bers of the MTBC into the phylogenetic tree of the complex
(Fig. 2).
Our work shows that by far the majority of human
tuberculosis cases (from M. tuberculosis) in South Africa
originate from active and ongoing transmission and not
reactivation disease and that this dynamic is valid for both
antibiotic-sensitive and resistant M. tuberculosis cases.
(Hanekom et al., 2007). Despite this enormous infection
pressure, there have been very few cases of confirmed an-
thropozoonotic TB in South Africa specifically, viz. a single
case of M. tuberculosis in a dog (Parsons et al., 2008b) and
one of M. tuberculosis in a zoo elephant (Tordiffe A et al.,
unpublished). However, a number of M. tuberculosis cases
in livestock have been reported in Ethiopia and other Afri-
can countries (Gumi et al., 2012).
Whilst the incidence and prevalence of M. bovis cases in
humans is far lower than M. tuberculosis, this pathogen is
problematic in various settings in animal and human
populations in the different countries. However, in south-
ern African countries (here defined as South Africa, Nami-
bia, Zimbabwe, Zambia, Tanzania, and Mozambique),
there are some considerable differences. In South Africa,
almost all M. bovis occurs in the wildlife population, due to
good disease control practice in the past, but historical
invasion into the African buffalo (Michel et al., 2007,
2009). Whilst it has spread into at least 12 mammal species,
it occurs predominantly in the wildlife parks, and there is
as yet no evidence to suggest spread across the interface
into humans or domestic livestock (Michel et al., 2010).
There are sporadic occurrences of M. bovis in domestic
herds, but these are apparently well controlled by state vet-
erinarians. Zimbabwe claimed to have no M. bovis (in the
past), whereas Zambia, Mozambique and Tanzania do. In
Zambia, M. bovis commonly occurs in wildlife in Kafue
(specifically lechwe) (Munyeme et al., 2009). In Mozam-
bique, M. bovis is found in a number of provinces in live-
stock, even up to a prevalence of 60% based on skin testing
in some districts (A Machado, personal communication).
In Tanzania, there is evidence for M. bovis in wildlife and
domestic stock (up to 13% positivity) and a few cases of
zoonotic M. bovis in humans have been reported (Katale
et al., 2012). As none of these countries can claim a full
diagnostic service with speciation, the true picture with
respect to zoonotic TB is unknown.
The social behaviour in captive and free-living animal
herds in African wildlife parks provide favourable condi-
tions for M. bovis transmission to members of the same
herd, for example buffalo in South Africa (Michel et al.,
2007, 2009) and lechwe in Zambia (Munyeme et al., 2009).
Transmission of the Mycobacterium tuberculosis complex
members is also effective in species that maintain social or
familial groups in underground dens. Drewe et al. con-
ducted a study in a South African meerkat population and
found that grooming (both giving and receiving) was more
likely than aggression to be correlated with mycobacterial
disease transmission and that groomers were at higher risk
of infection than groomees (Drewe et al., 2011).
Although respiratory transmission is probably the most
important route of infection in groups of animals that
remain in close contact, indirect transmission via food is
another important route (Kaneene and Thoen, 2004). For
oral transmission to occur, an uninfected animal has to
consume feed or water contaminated with mucous or nasal
secretions, faeces, or urine that contain the infective organ-
isms or receive milk from an infected dam; therefore, the
mycobacterium must be able to survive outside an infected
host for sufficient time to be ingested by another animal.
Research conducted in South Africa and elsewhere suggests
that infected buffalo serve as a source of direct oral infec-
tion to large predators such as lions and scavenging omni-
vores such as warthogs (Michel et al., 2007, 2009).
Fig. 2. The phylogeny of the Mycobacterium tuberculosis complex
(MTBC) members based on genome differences, which can form the
basis of differential diagnostics. Figure adapted from (Gey van Pittius
et al., 2012a,b).
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Non-tuberculous mycobacteria
Most of the species included in the genus Mycobacterium
are distinguished from theMycobacterium tuberculosis com-
plex members by the fact that they are not obligate patho-
gens, but are inhabitants of the environment. Although
these mycobacteria are classified as saprophytes and live
freely in the environment, they can be opportunistic patho-
gens, particularly in immunocompromised individuals.
This latter factor is of major concern in high HIV preva-
lence settings, such as those found in many parts of Africa.
For such individuals, there may be no such thing as a ‘non-
pathogenic’ mycobacterium.
Unlike tuberculosis caused by M. tuberculosis, which is
spread from human–human or human–animal or vice
versa, non-tuberculous mycobacterial infections have not
been considered to be particularly contagious (Brown,
1985). There is little or no evidence that the infection can
be transmitted from one person to another. Several reports
have debated the possibility of co-infection with both
M. tuberculosis and NTM in individuals (Shamaei et al.,
2010). The role of NTM, particularly when public health
issues are concerned, should nevertheless not be ignored,
despite the fact that no definitive route of transmission is
yet proposed. NTM and the pathologies they cause have
received increasing attention worldwide during the past
decade (Griffith et al., 2007), despite the fact that the
reported cases are still relatively few in numbers. Therefore,
any disease episode, especially those presenting with clinical
manifestations during their involvement merits being
reported, along with the major mycobacterial pathogens,
such as M. tuberculosis, M. leprae, M. avium and M. bovis
(Griffith et al., 2007).
About one-third of the NTM have thus far been associ-
ated with disease in humans and can cause localized disease
in the lungs, lymph glands, skin, wounds or bone (Katoch,
2004). From a human and clinical perspective, amongst the
most important slow-growing species are Mycobacterium
avium and Mycobacterium intracellulare (the M. avium
complex (MAC).
A recent clinical study in humans (Simons et al., 2011)
based on data from a number of geographically distant
regions in Asia showed that the M. avium complex was
responsible for 56% of clinically relevant pulmonary disease
(range 40–81%), M. abscessus for 35%, M. chelonae for
31%, M. kansasii and scrofulaceum for 17%, M. celatum
9%, M. szulgai 6%, M. fortuitum 5%, M. gordonae 2% and
M. terrae 1%. It is important to define what infection
means, illustrated by the following example: in Denmark
(Andrejak et al., 2010), 1282 adult humans were diagnosed
as NTM-positive, of which 26% had definite disease, 19%
possible disease and 55% colonization only. Five-year mor-
tality after definite NTM disease was 40.1%. Infection with
Mycobacterium xenopi was found to be associated with
worse prognosis than Mycobacterium avium complex.
Amongst 283 subjects studied in the USA (Yew et al.,
2011), 47% of them met American Thoracic Society/Infec-
tious Diseases Society of America (ATS/IDSA) pulmonary
NTM disease criteria for a minimum overall 2-year period
prevalence of 8.6/100,000 persons, and 20.4/100 000 in
those at least 50 years of age. The prevalence ranged from
1.4 to 6.6 per 100 000. The prevalence of NTM lung disease
globally appears to be increasing (Phillips and von Reyn,
2001; Petrini, 2006; Iseman and Marras, 2008; Moore et al.,
2010; Prevots et al., 2010) by over 2.8% per year, mostly
amongst persons older than 60 years of age, although in
most parts of the world, there is insufficient data to know
how universal this may be. Thus, although the prevalence
of disease from NTM may be low, the presence of NTM
species is associated with a high likelihood of disease and
thereafter mortality.
From such detailed reports in human studies, one may
reasonably assume that most if not all of these species could
cause TB-like disease in animal species and reports suggest
that the Mycobacterium avium complex (MAC, which
includes Mycobacterium intracellulare), Mycobacterium
kansasii, Mycobacterium malmoense, Mycobacterium xenopi,
Mycobacterium ulcerans, Mycobacterium fortuitum, Myco-
bacterium abscessus and Mycobacterium chelonae are indeed
found in a significant number of animals such as cattle,
deer, sheep and goats, as well as wild and domesticated
birds, fish, reptiles and amphibians (Karne et al., 2012)
(Bercovier and Vincent, 2001). However, it is important to
note that the presence of an NTM does not necessarily
imply an active disease process.
There are very few reports of NTM isolated from ani-
mals, especially from Africa. This is partly because of
the perception that NTM rarely cause disease (with the
exception of M. avium subsp paratuberculosis) and partly
because identification and speciation of NTM is rela-
tively complex. However, mycobacterial species (whether
in the MTBC or NTM) that have been identified to be
disease causing in African animals include M. goodii,
M.orygis and M. mungi, as well as a new species from
the meerkat (Suricata suricatta), as yet undescribed (Par-
sons et al., 2013).
The following NTM have been found to cause disease in
Africa: M. avium is the most frequent bacterial opportunis-
tic infection of AIDS (Karne et al., 2012); M. fortuitum is
most frequently isolated from fish and was found to pro-
duce a high mortality rate in South African fish farms
(Bragg et al., 1990); M. senegalense has been implicated in
tuberculosis-like pathology of cattle in Africa (Bercovier
and Vincent, 2001). Whether a single agent is responsible
for bovine farcy is still unclear, although Chamoiseau con-
sidered M. farcinogenes var. senegalense and M. farcinogenes
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var. tchadense to be the sole agents of bovine farcy because
of the isolation of these species from the lesions (Chamoi-
seau, 1973). M. kansasii has been detected in humans as
well as in wild animals such as deer, camels, birds, monkeys
and in water (which may be the natural reservoir) and was
one of the first species shown to be responsible for non-
tuberculous pulmonary infection (Bercovier and Vincent,
2001). The impact of this important pathogen in human
infection is regularly reported and is considerable; however,
it is a relatively rare pathogen of animals (Bercovier and
Vincent, 2001).
Over the past few years, we have prepared various animal
samples for mycobacterial culture analysis when necropsy
has been carried out as part of routine practice. Cultures
obtained from bronchial washes, lymph nodes and lung
material include the following species identified by 16S
rRNA sequence analysis: M. abcessus, M. asiaticum,
M. avium, M. brasilienses, M. chelonae, M. elephantis,
M. engbackii, M. farcinogenes, M. fortuitum, M. gilven,
M. gordonae, M. heraklionense, M. hiberniae, M. intracellu-
lare, M. interjectum, M. lentiflavum, M. marseillense,
M. moriokaense, M. nonchromogenicum, M. palustre,
M. palveris, M. paraffinicum, M. phlei, M. senegalense,
M. simiae, M. sherrisii, M. sphagni, M. terrae and
M. vulneris. Animal species examined were lions, rhinos,
banded mongooses, cattle, baboons, elephants and mon-
keys. The presence and isolation of these mycobacteria does
not imply active disease in each case. However, should any
animal become immunocompromised, many species could
be pathogenic. Thus, with rare exceptions, we have
observed that mycobacterial species other than M. tubercu-
losis, M. bovis and M. avium subsp. paratuberculosis, sel-
dom cause extensive disease, and very few reports exist in
the literature.
Geographical distribution and environmental
determinants
There is a reasonable body of literature regarding the distri-
bution of the MTBC, but little concerning NTM. These will
both be discussed briefly below. Regional variations in the
geographical distribution of mycobacteria in Asia are
reported, and it is reasonable to expect a similar variation
across Africa (Simons et al., 2011). Certainly, for example,
this is supported by the localized occurrence of mycobacte-
rial species such as M. cannetti, M. ulcerans and subtypes
of M. bovis. Specifically, M. ulcerans and M. bovis Af1 sub-
types are found predominantly in west Africa (Niemann
et al., 2000), M cannetti in the Horn of Africa (Pfyffer
et al., 1998), M. bovis Af2 subtype in east Africa (Niemann
et al., 2000), M. mungi in Botswana (Alexander et al.,
2010) and the dassie bacillus and M. suricattae thus far
in South Africa only (Parsons et al., 2008a, 2013). Factors
playing a role in distribution may include initial host range
and topography, host specificity and host susceptibility.
Environmental factors leading to previously unrecorded
species appearing sporadically in other regions can be as a
result of travel of animals, humans or birds, for example
(De Groote and Huitt, 2006; Griffith et al., 2007). Alterna-
tively, the apparent absence of a species from an area may
simply be because no survey or relevant diagnostic work
has been done there.
With the exception of M. ulcerans, these are all members
of the M. tuberculosis complex, and this biodiversity sug-
gests a possible origin for the M. tuberculosis complex to be
‘Out of Africa’, with regional evolution to explain the
emergence of different strains or species of mycobacteria.
Further evidence to support this ‘Out of Africa’ suggestion
comes from work done in Ethiopia, where a new M. tuber-
culosis lineage has been found, which is restricted to the
Ethiopian highlands (Berg et al., 2011).
The distribution of NTM may be regional or global: for
example, the M. avium complex, M. abscessus, M. scrofula-
ceum, M. marinum and M. fortuitum are encountered
globally, whilst M. malmoense is found mainly in Scandina-
via (Griffith et al., 2007) and M. ulcerans mainly in Austra-
lia, Africa and South-East Asia (the tropics) (Ablordey
et al., 2005). In Chad and Nigeria, the M. fortuitum com-
plex was most frequently isolated from cattle and pigs
(respectively) when they conducted a study to investigate
tuberculosis (Bercovier and Vincent, 2001). Similarly, path-
ogenic NTMs isolated from the pastoral ecosystems of
Uganda included the M. avium complex (Muller et al.,
2008).
Because of the presence of NTM in the environment,
human activities have had direct impacts on their ecology
and hence their epidemiology (Kankya et al., 2011) as
humans have very substantially altered the living environ-
ment (Falkinham, 2010). This may provide new niches that
some mycobacteria can exploit and thereby increase our
risk of exposure. An example of this is water supply sys-
tems, where mycobacteria can easily form biofilms, which
are almost impossible to remove (Falkinham, 2011). In all
the habitats, where NTM have been recovered (Michel
et al., 2007), the mycobacteria are part of the normal flora,
existing as stable, resident and growing populations. An
exception may be M. avium subsp. paratuberculosis, where
growth and persistence in the environment has not been
reported, despite being prevalent in Bovidae worldwide.
Farms or settlements with persistent infection have been
described as sources of infection in this case (Whittington
et al., 2005).
Compared with other bacteria, NTM are relatively disin-
fectant, heavy metal, and antibiotic resistant. Thus, the use
of any anti-microbial agent selects for mycobacteria.
Employment of disinfectants for drinking water treatment
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leads to selection and enrichment of mycobacteria in distri-
bution systems in the absence of disinfectant-sensitive
competing micro-organisms (Falkinham, 2010, 2011).
Non-tuberculous mycobacteria selection may also occur as
a consequence of the presence of antibiotics in drinking
water and drinking water sources. Likewise, pollution, large
scale agriculture, human and animal movement and a myr-
iad of activities can provide micro-organisms in general
and mycobacteria specifically with a rich opportunity to
move and exploit their environment (Falkinham, 2010,
2011).
Discovery that human behaviours lead to selection and
proliferation of NTM in habitats occupied by both humans
and NTM, creates the dilemma that human actions taken
to reduce pathogen exposure (i.e. water disinfection), lead
to possible increased NTM disease (Petrini, 2006; Moore
et al., 2010; Prevots et al., 2010; Yew et al., 2011).
Hosts of mycobacteria
Some individuals (and species or strains of animals) are
more susceptible to mycobacterial disease than others. For
example, in cattle, it has been shown that various breeds
have differing susceptibility to bovine TB (Ameni et al.,
2007). Additionally, there is evidence to suggest that differ-
ent populations of hosts may also select for certain patho-
gen types or subtypes (Hanekom et al., 2007).
Although it is largely M. tuberculosis that is found in
active TB humans and M. bovis in terrestrial animals,
Mycobacterium species can cross the species barrier in both
the zoonotic and anthropozoonotic directions. Thus, cases
of M. bovis in humans are well known, but less commonly,
cases of M. tuberculosis have been reported in animals such
as cats, dogs and elephants (Parsons et al., 2008b; Angkaw-
anish et al., 2010; LoBue et al., 2010), where the sources of
these infections have commonly been traced to infected
humans. However, there are many cases of M. tuberculosis
in animal collections, where it is arguably an important
cause of morbidity and mortality from infectious disease in
captive wildlife (Montali et al., 2001). Transmission of
M. tuberculosis from animal to animal has not been conclu-
sively shown, although extensive transmission is found with
the animal-adapted species of the complex, such as M. bo-
vis. Parsons et al. showed thatM. tuberculosis antigens were
found in 50% of dogs living in close contact with sputum
smear-positive TB patients (Parsons et al., 2012). As South
Africa is rated as a high TB incidence and risk setting, it is
not surprising that companion animals living in such envi-
ronments will be exposed to this pathogen. Whether these
animals can be reservoirs for human disease, in turn, is not
known. Despite these cases of M. tuberculosis in animals,
most free-living animals diagnosed as tuberculous are
reported or regarded to be infected with M. bovis;
therefore, infection with M. bovis is of public-health and
economic importance.
However, the complex members also cause TB; even if
they show limited host or geographical association (see
Table 1). For example, the recently described M. orygis
(Gey van Pittius et al., 2012a,b; van Ingen et al., 2012b) is
apparently host-adapted to the antelope and found almost
exclusively in the Arabian oryx (Oryx leucoryx) in the Mid-
dle East. However, the first isolation of this species in South
Africa was from an African buffalo (Gey van Pittius et al.,
2012a,b), although the history of this animal suggests that
contact with Arabian oryx was highly likely at some stage.
This finding shows that infected animals with host-adapted
pathogens which may at first appear to be host specific can
sometimes infect a new host species.
Clinical signs and diagnoses
Rapid diagnoses of animals infected with M. tuberculosis or
M. bovis are performed using two primary immunological
tests, namely the in vitro tuberculin skin test (TST) and the
in vivo interferon-gamma (IFN-c) release assay (IGRA).
These tests typically rely on the detection of antigen-specific
T lymphocyte-mediated responses as surrogate markers of
infection by the causative organism. The IGRAs now
include proteins largely specific to M. tuberculosis and
M. bovis, such as early secretory antigenic target 6 kDa
(ESAT-6) and culture filtrate protein 10 kDa (CFP-10), for
better diagnoses. These tests generally indicate infection
and not active disease and are also not able to speciate (dif-
ferentiate) the pathogen or definitively diagnose an infec-
tion or disease caused by an NTM. However, once a
positive culture of NTM has been obtained, the Capilia TB
assay was found to be a quick and easy test to use for differ-
Table 1. Mycobacterium tuberculosis complex species and their host
association
Species Host (s)
Found in
southern
Africa
M. tuberculosis Humans Yes
M. canetti Humans No
M. africanum Humans No
M. mungi Banded mongoose Yes
Dassie bacillus Dassies Yes
M. orygis Arabian oryxes Yes
M. microti Voles, mice, shrews No
M. pinnipedii Sea lions, fur seals No
M. caprae Goats No
M. bovis Bovids mainly, array
of mammalian hosts
Yes
Note: this table is based on published data and is accurate as of June
2012.
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entiation between the Mycobacterium tuberculosis complex
and NTM culture isolates (Kaufmann, 2002; de la Rua-
Domenech et al., 2006; Muyoyeta et al., 2010).
Because of the high incidence of M. bovis detected in a
wide variety of animal species (and very high incidence of
M. tuberculosis in humans) in Africa, it is not surprising
that less emphasis is put on the diagnoses of NTM infec-
tion. This is the case in animals, even if the animal has
tested positive for PPDAvium. It is particularly true in areas
of high M. tuberculosis complex prevalence. In the face of a
high disease burden from M. tuberculosis and M. bovis,
many underdeveloped nations with inadequate health bud-
gets do not devote any attention to NTM infection, where
the literature mostly reports an NTM incidence rate of less
than 5/100 000. However, recent studies in South and
southern Africa show that one is likely to isolate NTM
from people suspected to have TB, at a rate at least equal
to that with which M. tuberculosis is found. In fact, in
some communities with a high prevalence of TB, far more
NTM than M. tuberculosis have been isolated from subjects
(Muyoyeta et al., 2010; Chihota et al., 2012). From the dis-
ease and infection control perspective, it is important to
know whether one is dealing with disease due to M. tuber-
culosis complex or NTM, as antibiotic susceptibility and
control may differ. For example, in animal health work,
the discovery of TB-like lesions in a livestock animal dur-
ing necropsy and the easily derived but possibly incorrect
diagnosis of M. bovis infection (Muller et al., 2011) may
have devastating and unnecessary consequences for the
herd owner.
However, NTM are increasingly identified due to better
detection and speciation by PCR (Warren et al., 2006) or
target gene sequencing. Clinical signs of NTM disease man-
ifestation vary depending on the extent and location of the
lesions. NTM disease most commonly presents as pulmo-
nary manifestations (Cook, 2010). However, lymph node,
skin and soft tissue involvement, as well as disseminated
disease, are of clinical importance. Clinical presentation of
pulmonary disease due to NTM may be similar to tubercu-
losis with the following clinical signs: low fever, night
sweats, anaemia and weight loss, malaise, anorexia, diar-
rhoea and painful adenopathy in humans and in animals
(Katoch, 2004). Clinical diagnosis of tuberculosis is usually
possible only after the disease has reached an advanced
stage and is dependent on the site of lesions. At the time of
diagnosis, most infected hosts may have shed bacilli and
have been or are a potential source of infection for other
hosts.
As it is relatively difficult to isolate, culture and speciate
mycobacteria, as well as decide whether the presence of that
organism is simply colonization, or infection and disease,
the literature on many of the complex species and for NTM
is not definitive. Isolation may simply represent recent
acquisition, colonization without disease or infection with
disease implying clinical manifestation of tissue damage (at
either micro or visible scale). Additionally, as NTM are
ubiquitous, great care must be exercised with sampling, as
environmental contamination could occur (Hatherill et al.,
2006). It is clear that care must be taken in interpretation
of diagnostic reports: if the only laboratory-based test used
is a ZN (Ziehl-Neelsen) smear, then acid fastness may be
over-interpreted as TB positive (M. tuberculosis or perhaps
M. bovis) and dealt with accordingly, but incorrectly under
the directly observed therapy, short-course (DOTS) pro-
gramme. Directly observed therapy, short-course treatment
for human pulmonary tuberculosis is started only on the
basis of sputum microscopy results, which has an inherent
possibility of misdiagnosing NTM disease, with subsequent
incorrect treatment. For example, it has been noted that
some of the cases that are identified as anti-TB treatment
failure or suspected as drug resistance are actually due to
NTM (Griffith et al., 2007).
Conclusion
Although the burden of disease from M. tuberculosis or
M. bovis is apparently orders of magnitude higher than that
from NTM, the latter can potentially carry a relatively high
burden of morbidity and mortality as they may be difficult
to diagnose and treat (van Ingen et al., 2012a). For the pur-
poses of mycobacterial disease control, care must be exer-
cised where diagnosis is based only on macroscopic
examination and perhaps smear or simple culture positivity
or immunological reactivity. We do not yet clearly under-
stand the disease-causing potential of the various mycobac-
teria in different animal species or the risk factors and
drivers that may promote such disease, as opposed to expo-
sure and infection. Our lack of such knowledge impacts on
our ability to control these diseases and generate useful effi-
cacious vaccines. The public-health threat of tuberculosis
in Africa requires urgent investigation on this topic
through collaborative veterinary and medical research pro-
grammes.
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